Reproducibility of the CROSS Trial Results in the Multimodal Treatment of Esophageal Cancer in Daily Practice: A Single Center Retrospective Observational Study.

Background: Treatment of nonmetastatic esophageal cancer with curative intention remains a major challenge. Neoadjuvant radiochemotherapy followed by surgery, as described in the CROSS trial in 2012, has been established as a standard of care. With this retrospective observational study, we aimed to analyze the results of the CROSS regimen in daily practice over the last 10 years at the St.

Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.

Evidence from a few small randomized trials and retrospective cohorts mostly including various tumor entities indicates a prolongation of disease free survival (DFS) and overall survival (OS) from local ablative therapies in oligometastatic disease (OMD). However, it is still unclear which patients benefit most from this approach. We give an overview of the several aspects of stereotactic body radiotherapy (SBRT) in extracranial OMD in breast cancer from a radiation oncology perspective.

Long-Term Results of the TARGIT-A Trial: More Questions than Answers.

Background: During the last decade, partial breast irradiation (PBI) has gained traction as a relevant treatment option for patients with early-stage low-risk breast cancer after breast-conserving surgery. The TARGIT-A prospective randomized trial compared a "risk-adapted" intraoperative radiotherapy (IORT) approach with 50-kv X-rays (INTRABEAM®) as the PBI followed by optional whole-breast irradiation (WBI) and conventional adjuvant WBI in terms of observed 5-year in-breast recurrence rates. Recently, long-term data were published.

Spectro-dosemeter-based gamma dose rate network in Germany.

As a consequence of the Chernobyl accident in 1986 the Integrated Measurement and Information System (IMIS) was established (Weiss and Leeb, 1993) which includes on-line monitoring networks for the surveillance of radioactivity in Germany. Today, the German Federal Office for Radiation Protection (BfS) operates a gamma dose rate network with 1800 ambient dose equivalent rate H*(10) (ADER) stations almost equally distributed over the German territory. The ADER network integrates Geiger-Müller (GM) based detectors which, if low and high dose rate tubes are combined, are known to have excellent long-term stability and an extended dose rate range from environmental background level (20 nSv/h) up to several Sv/h.